Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKesson
Merck
Dow
Boehringer Ingelheim

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Binimetinib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for binimetinib and what is the scope of freedom to operate?

Binimetinib is the generic ingredient in one branded drug marketed by Array Biopharma Inc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Binimetinib has two hundred and two patent family members in fifty-one countries.

One supplier is listed for this compound.

Summary for binimetinib
International Patents:202
US Patents:11
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 66
Clinical Trials: 37
Patent Applications: 162
DailyMed Link:binimetinib at DailyMed
Recent Clinical Trials for binimetinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hospices Civils de LyonN/A
University of California, San FranciscoPhase 1/Phase 2
UNICANCERPhase 2

See all binimetinib clinical trials

Synonyms for binimetinib
181R97MR71
5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
5-(4-Bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
5-[(4-Bromo-2-Fluorophenyl)Amino]-4-Fluoro-N-(2-Hydroxyethoxy)-1-Methyl-1H-Benzimidazole-6-Carboxami
5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
6-(4-bromo-2-fluoroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide
6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide
6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
606143-89-9
A11493
AB0095018
AC-29023
ACWZRVQXLIRSDF-UHFFFAOYSA-N
AK175886
AKOS026750517
AOB2072
ARRY 162
ARRY 438162
ARRY-162
ARRY-162,MEK-162
ARRY-162; ARRY-438162; MEK 162; ARRY 162; ARRY 438162
ARRY-438162
AS-16706
BC600594
BCP06780
Binimetinib (JAN/USAN)
Binimetinib (MEK162, ARRY-162, ARRY-438162)
Binimetinib [USAN:INN]
Binimetinib;MEK-162; ARRY-162;ARRY-438162
C17H15BrF2N4O3
cas:606143-89-9;MEK162
CHEMBL3187723
CS-0627
D10604
DB11967
DTXSID70209422
EX-A1024
FT-0697088
GTPL7921
HMS3652J14
HY-15202
J-516581
KS-0000062X
MEK-162
MEK162
MEK162 (ARRY-162, ARRY-438162)
MEK162 (Arry-162)
MEK162(Binimetinib)
Mektovi
MFCD22124525
MLS006011180
NCGC00345804-01
NCGC00345804-10
NVP-MEK162
QCR-138
RL04283
s7007
SB16501
SCHEMBL570088
SMR004702949
SW219910-1
UNII-181R97MR71
W-5894
Y1468
ZINC38460704

US Patents and Regulatory Information for binimetinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   See Pricing   See Pricing   See Pricing
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   See Pricing   See Pricing   See Pricing
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   See Pricing   See Pricing   See Pricing
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   See Pricing   See Pricing   See Pricing
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   See Pricing   See Pricing Y Y   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for binimetinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2727918 CA 2019 00013 Denmark   See Pricing PRODUCT NAME: KOMBINATION AF BINIMETINIB OG ENCORAFENIB, I ALLE FORMER HVERT ISAER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1315 ELLER EU/1/18/1314 20180924
2470526 300973 Netherlands   See Pricing DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2470526 PA2019005 Lithuania   See Pricing PRODUCT NAME: ENKORAFENIBAS BET KOKIOMIS FORMOMIS, KURIOMS TAIKOMA PAGRINDINIO PATENTO APSAUGA; REGISTRATION NO/DATE: EU/1/18/1314 20180920
2727918 300975 Netherlands   See Pricing PRODUCT NAME: COMBINATIE VAN BINIMETINIB EN ENCORAFENIB, BEIDE IN ALLE VORMEN ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/18/1314 20180924
1482932 LUC00100 Luxembourg   See Pricing PRODUCT NAME: MEKTOVI - BINIMETINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1315 20180924
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Harvard Business School
Johnson and Johnson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.